Regenerative Medical Technology Group net loss widens to US$876,274 in Q1 FY26; revenue rises 93.45% to US$2.64 million

REGENERATIVE MEDICAL TECHNOLOGY GROUP INC

REGENERATIVE MEDICAL TECHNOLOGY GROUP INC

RMTG

0.00
  • Regenerative Medical Technology Group posted a net loss of US$ 876,274, widening 15.29% from a year earlier.
  • Revenue rose to US$ 2.64 million, nearly doubling year over year, while operating income climbed 70.26% to US$ 229,783.
  • Interest expense jumped to US$ 2.19 million, up 145.07%, partly offset by a US$ 1.08 million gain from derivative revaluation.
  • Cash and cash equivalents increased 10.95% to US$ 1.06 million; net cash from operations rose to US$ 102,124.
  • Management cited progress on 2026 priorities, including scaling Cellgenic output, advancing a clinic franchise model, and developing an ISSCA AI platform and mobile app.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenerative Medical Technology Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-066838), on June 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.